{"id":14039,"date":"2004-11-30T13:13:59","date_gmt":"2004-11-30T12:13:59","guid":{"rendered":"http:\/\/miunidad.eu\/porib.com\/?p=14039"},"modified":"2022-09-15T13:01:01","modified_gmt":"2022-09-15T11:01:01","slug":"buti-m-casado-ma-fosbrook-l-esteban-r-2","status":"publish","type":"post","link":"https:\/\/porib.com\/en\/buti-m-casado-ma-fosbrook-l-esteban-r-2\/","title":{"rendered":"Buti M, Casado MA, Fosbrook L, Esteban R"},"content":{"rendered":"<div class=\"col80\">\n<p class=\"miniatura_foto\" style=\"text-align: justify;\"><strong><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-14040 alignleft\" src=\"https:\/\/porib.com\/wp-content\/uploads\/2021\/08\/AASLD.jpg\" alt=\"\" width=\"120\" height=\"120\" \/>Buti M, Casado MA, Fosbrook L, Esteban R<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<div class=\"col80p\">\n<h6 style=\"text-align: justify;\">Budget impact analysis of two different methods of evaluating EVR to peginterferon alfa-2b (PegIntron?) plus ribavirin (Rebetol) in genotype 1 na\u00efve patients with chronic hepatitis C<\/h6>\n<h6 style=\"text-align: justify;\"><strong>55th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, Massachusetts, EEUU. 29 oct-2 nov 2004<\/strong><\/h6>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Buti M, Casado MA, Fosbrook L, Esteban R &nbsp; &nbsp; &nbsp; Budget impact analysis of two different methods of evaluating EVR to peginterferon alfa-2b (PegIntron?) plus ribavirin (Rebetol) in genotype 1 na\u00efve patients with chronic hepatitis C 55th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, Massachusetts, EEUU. 29&#8230; <\/p>\n<div class=\"clear\"><\/div>\n<p><a href=\"https:\/\/porib.com\/en\/buti-m-casado-ma-fosbrook-l-esteban-r-2\/\" class=\"excerpt-read-more\">Read More<i class=\"fa fa-caret-right icon-caret-right\"><\/i><\/a><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"quote","meta":{"footnotes":""},"categories":[116,919,196],"tags":[],"class_list":["post-14039","post","type-post","status-publish","format-quote","hentry","category-ace-acu-tipo-de-proyecto","category-enfermedades-autoinmunes","category-aasd","post_format-post-format-quote"],"translation":{"provider":"WPGlobus","version":"2.10.3","language":"en","enabled_languages":["es","en"],"languages":{"es":{"title":true,"content":true,"excerpt":false},"en":{"title":false,"content":false,"excerpt":false}}},"_links":{"self":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/14039"}],"collection":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/comments?post=14039"}],"version-history":[{"count":3,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/14039\/revisions"}],"predecessor-version":[{"id":14043,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/14039\/revisions\/14043"}],"wp:attachment":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/media?parent=14039"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/categories?post=14039"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/tags?post=14039"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}